Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Myriad Genetics, Inc.

Myriad Genetics, Inc. (MYGN) Stock Overview

Explore Myriad Genetics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

MYGN●NASDAQ
HealthcareMedical - Diagnostics & Research
$6.19
$0.12(1.90%)
U.S. Market opens in 15h 14m

Myriad Genetics, Inc. (MYGN)

Meyka AI Score

Z

Key Financials

Market Cap584.6M
P/E Ratio-1.42
EPS (TTM)$-0.13
ROE-1.09%
Fundamental Analysis

AI Price Forecasts

1 Month$5.43
3 Months$11.57
1 Year Target$0.00

MYGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Myriad Genetics, Inc. (MYGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.42 and a market capitalization of 584.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.90%
5-Day Change
1.14%
1-Month Change
45.65%
3-Month Change
23.80%
6-Month Change
4.56%
Year-to-Date (YTD) Change
0.65%
1-Year Change
22.33%
3-Year Change
-72.65%
5-Year Change
-79.90%
All-Time (Max) Change
15.06%

Contact Information

https://www.myriad.com
801 584 3600
322 North 2200 West, Salt Lake City, UT, 84116

Company Facts

27,250 Employees
IPO DateOct 6, 1995
CountryUS
Actively Trading

Frequently Asked Questions